Evidence map›Paper›PMID 37344606›Full record

ArticleJournal of cancer research and clinical oncology2023

Impact of positive microscopic resection margins (R1) after gastrectomy in diffuse-type gastric cancer.

Sérgio Gaspar-Figueiredo, Pierre Allemann, Alexander B J Borgstein, Gaëtan-Romain Joliat, Valentine Luzuy-Guarnero, Christophe Brunel, Christine Sempoux, Suzanne Sarah Gisbertz, Nicolas Demartines, Mark Ivo van Berge Henegouwen and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Impact of resection margin status on survival in gastric cancer: A retrospective cohort study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  3. R1 Resection in Gastric Cancer: Marker of Tumor Biology Rather Than Surgical Failure.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Sérgio Gaspar-Figueiredo *Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-0883-9690
Pierre Allemann *Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-6495-7096
Alexander B J BorgsteinDepartment of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-5179-1207
Gaëtan-Romain JoliatDepartment of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-8725-3494
Valentine Luzuy-GuarneroDepartment of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-2276-0794
Christophe BrunelFaculty of Biology and Medicine, University of Lausanne UNIL, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-2948-7310
Christine SempouxFaculty of Biology and Medicine, University of Lausanne UNIL, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-1375-3979
Suzanne Sarah GisbertzDepartment of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-9655-7601
Nicolas DemartinesDepartment of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-1530-3114
Mark Ivo van Berge HenegouwenDepartment of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8689-3134
Markus SchäferDepartment of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland. markus.schafer@chuv.ch.ORCID http://orcid.org/0000-0003-4335-4098
Styliani MantziariDepartment of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-1315-1898
University of Lausanne · CHAmsterdam University Medical Centers · NLUniversity Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiffuse-type gastric cancer (DTGC) is associated with poor outcome. Surgical resection margin status (R) is an important prognostic factor, but its exact impact on DTGC patients remains unknown. The aim of this study was to assess the prognostic value of microscopically positive margins (R1) after gastrectomy on survival and tumour recurrence in DTGC patients.

methodsAll consecutive DTGC patients from two tertiary centers who underwent curative oncologic gastrectomy from 2005 to 2018 were analyzed. The primary endpoint was overall survival (OS) for R0 versus R1 patients. Secondary endpoints included disease-free survival (DFS), recurrence patterns as well as the overall survival benefit of chemotherapy in this DTGC patient cohort.

resultsOverall, 108 patients were analysed, 88 with R0 and 20 with R1 resection. Patients with negative lymph nodes and negative margins (pN0R0) had the best OS (median 102 months, 95% CI 1-207), whereas pN + R0 patients had better median OS than pN + R1 patients (36 months 95% CI 13-59, versus 7 months, 95% CI 1-13, p < 0.001). Similar findings were observed for DFS. Perioperative chemotherapy offered a median OS of 46 months (95% CI 24-68) versus 9 months (95% CI 1-25) after upfront surgery (p = 0.022). R1 patients presented more often early recurrence (< 12 postoperative months, 30% vs 8%, p = 0.002), however, no differences were observed in recurrence location.

conclusionDTGC patients with microscopically positive margins (R1) presented poorer OS and DFS, and early tumour recurrence in the present series. R0 resection should be obtained whenever possible, even if other adverse biological features are present.

Indexed as

Stomach NeoplasmsGastrectomyHumansMargins of ExcisionNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateDrug therapyMargins of excisionRecurrenceStomach neoplasmsSurvival rate

Identifiers

PMID37344606
PMCPMC10465620
OpenAlexW4381549340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.